VCNXVaccinex, Inc.

About Vaccinex, Inc. (VCNX)

Vaccinex, Inc. (VCNX) is a Biotechnology company headquartered in Rochester, NY, United States whose shares trade over-the-counter on the Pink tier.

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses.

VCNX key facts

Ticker symbol

VCNX

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Rochester, NY, United States

Country of incorporation

US

Estimated market cap

$1.95M (as of Apr 10, 2025)

Shares outstanding

2,676,637

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Latest filing

8K Report (Mar 18, 2025)

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with V